USP6NL intronic transcript 1 (non-protein coding), transcript variant 1: A Drug Target / Disease Biomarker

Target Name: USP6NL intronic transcript 1 (non-protein coding), transcript variant 1

NCBI ID: G100507213

USP6NL intronic transcript 1 (non-protein coding), transcript variant 1

Other Name(s): USP6NL-IT1 variant 1

USP6NL intronic transcript 1 (non-protein coding), transcript variant 1: A Drug Target / Disease Biomarker

USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 is a non-protein coding RNA molecule that has been identified as a potential drug target or biomarker. The USP6NL gene is located on chromosome 16p31 and encodes a protein known as USP6NL, which is a nuclear export protein that is involved in the export of proteins from the nuclear envelope to the cytoplasm. USP6NL has been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and transcriptional regulation.

In recent years, researchers have become increasingly interested in USP6NL as a potential drug target due to its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. USP6NL has also been shown to be overexpressed in several types of cancer, including breast, ovarian, and colorectal cancer.

One of the reasons for the interest in USP6NL as a drug target is its unique structure. USP6NL is a 16.8 kDa protein that consists of a cytoplasmic domain and a transmembrane domain. The cytoplasmic domain contains a N-terminal transmembrane domain that is involved in protein-protein interactions and may be a potential drug target. The transmembrane domain is involved in the regulation of protein stability and localization to the cytoplasm.

Another reason for the interest in USP6NL is its role in several cellular processes. USP6NL has been shown to play a role in the regulation of cell cycle progression, apoptosis, and transcriptional regulation. It has been shown to interact with several cellular signaling pathways, including the PI3K/Akt signaling pathway, the NF-kappa-B signaling pathway, and the TGF-β signaling pathway.

In addition to its role in cellular processes, USP6NL has also been shown to be involved in several diseases. For example, USP6NL has been shown to be overexpressed in several types of cancer, including breast, ovarian, and colorectal cancer. It has also been shown to be involved in the regulation of several diseases, including neurodegenerative diseases and autoimmune disorders.

Overall, USP6NL is a non-protein coding RNA molecule that has been shown to play a role in several cellular processes and is potential drug target or biomarker. Further research is needed to fully understand its role in diseases and its potential as a drug.

Protein Name: USP6NL Intronic Transcript 1 (non-protein Coding), Transcript Variant 1

The "USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets